Compounds > pyrazines
Page last updated: 2024-08-21

pyrazines and oblimersen

pyrazines has been researched along with oblimersen in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Giles, FJ1
Cheson, BD1
Kaplow, R1
Chan, KK; Chanan-Khan, A; Frankel, S; Liu, S; Marcucci, G; O'Connor, OA; Rolfe, M; Smith, EA; Teruya-Feldstein, J; Toner, LE; Wei, X1

Reviews

3 review(s) available for pyrazines and oblimersen

ArticleYear
New drugs in acute myeloid leukemia.
    Current oncology reports, 2002, Volume: 4, Issue:5

    Topics: Acute Disease; Adenine Nucleotides; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Azacitidine; Bevacizumab; Boronic Acids; Bortezomib; Clofarabine; Cytosine; Decitabine; Dioxolanes; Humans; Indoles; Leukemia, Myeloid; Phthalazines; Pyrazines; Pyridines; Pyrroles; Thionucleotides

2002
Hematologic malignancies: new developments and future treatments.
    Seminars in oncology, 2002, Volume: 29, Issue:4 Suppl 13

    Topics: Adenine Nucleotides; Alemtuzumab; Alkaloids; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cell Cycle; Cell Survival; Clofarabine; Cytosine; Dioxolanes; Flavonoids; Hematologic Neoplasms; Humans; Immunoconjugates; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Multiple Myeloma; NF-kappa B; Nitrogen Mustard Compounds; Oligonucleotides, Antisense; Peptide Hydrolases; Piperidines; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Remission Induction; Rituximab; Staurosporine; Thionucleotides

2002
Innovations in antineoplastic therapy.
    The Nursing clinics of North America, 2005, Volume: 40, Issue:1

    Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate

2005

Other Studies

1 other study(ies) available for pyrazines and oblimersen

ArticleYear
The combination of the proteasome inhibitor bortezomib and the bcl-2 antisense molecule oblimersen sensitizes human B-cell lymphomas to cyclophosphamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, May-01, Volume: 12, Issue:9

    Topics: Animals; Boronic Acids; Bortezomib; Cell Division; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Genes, bcl-2; Humans; Kinetics; Lymphoma, B-Cell; Mice; Mice, SCID; Oligonucleotides, Antisense; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Thionucleotides; Transplantation, Heterologous

2006